Objective neurocognitive functioning and neurocognitive complaints in patients with high-grade glioma

Autor: Martin J. van den Bent, Martin Klein, Andrew Bottomley, Wolfgang Wick, Jos W. R. Twisk, Jaap C. Reijneveld, A Josephine Drijver, Ahmed Idbaih, Madeline Pe, Ivan Caramanna
Přispěvatelé: Neurology, unité de recherche de l'institut du thorax UMR1087 UMR6291 (ITX), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN), Vrije Universiteit Amsterdam [Amsterdam] (VU), European Organisation for Research and Treatment of Cancer [Bruxelles] (EORTC), European Cancer Organisation [Bruxelles] (ECCO), VU University Medical Center [Amsterdam], Erasmus University Medical Center [Rotterdam] (Erasmus MC), Institut du Cerveau et de la Moëlle Epinière = Brain and Spine Institute (ICM), Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), Heidelberg University Hospital [Heidelberg], Clinical Neuropsychology, Medical psychology, Epidemiology and Data Science, APH - Health Behaviors & Chronic Diseases, APH - Methodology, CCA - Cancer Treatment and quality of life, Gestionnaire, HAL Sorbonne Université 5, Unité de recherche de l'institut du thorax (ITX-lab), Institut du Cerveau = Paris Brain Institute (ICM), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS)
Jazyk: angličtina
Rok vydání: 2021
Předmět:
0301 basic medicine
Male
Health Knowledge
Attitudes
Practice
Cancer Research
Cognition Disorders/etiology
Health-related quality of life
Neuropsychological Tests
Correlation
High-grade glioma
0302 clinical medicine
Quality of life
Surveys and Questionnaires
Medicine
Practice
Brain Neoplasms
Health Knowledge
Cognition
Glioma
Middle Aged
Mental Status and Dementia Tests
Prognosis
humanities
3. Good health
Europe
Oncology
030220 oncology & carcinogenesis
[SDV.NEU]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]
Female
Clinical psychology
Cognitive awareness
Concordance
[SDV.CAN]Life Sciences [q-bio]/Cancer
Glioma/complications
03 medical and health sciences
[SDV.CAN] Life Sciences [q-bio]/Cancer
SDG 3 - Good Health and Well-being
Humans
[SDV.NEU] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]
Cognitive skill
business.industry
Cancer
medicine.disease
Clinical trial
Neurocognitive functioning
030104 developmental biology
Cross-Sectional Studies
Brain Neoplasms/complications
Attitudes
Quality of Life
PROs
Cognition Disorders
business
Neurocognitive
Follow-Up Studies
Zdroj: European Journal of Cancer, 144, 162-168. Elsevier Ltd.
European Journal of Cancer
European Journal of Cancer, Elsevier, 2020, 144, pp.162-168. ⟨10.1016/j.ejca.2020.10.040⟩
European Journal of Cancer, 144, 162-168. Elsevier Limited
European Journal of Cancer, 144, 162-168. Pergamon
European Journal of Cancer, 2020, 144, pp.162-168. ⟨10.1016/j.ejca.2020.10.040⟩
Caramanna, I, Bottomley, A, Drijver, A J, Twisk, J, van den Bent, M, Idbaih, A, Wick, W, Pe, M, Klein, M, Reijneveld, J C & EORTC Quality of Life Group and Brain Tumour Group 2021, ' Objective neurocognitive functioning and neurocognitive complaints in patients with high-grade glioma : Evidence of cognitive awareness from the European Organisation for Research and Treatment of Cancer brain tumour clinical trials ', European Journal of Cancer, vol. 144, pp. 162-168 . https://doi.org/10.1016/j.ejca.2020.10.040
EORTC Quality of Life Group and Brain Tumour Group 2021, ' Objective neurocognitive functioning and neurocognitive complaints in patients with high-grade glioma : Evidence of cognitive awareness from the European Organisation for Research and Treatment of Cancer brain tumour clinical trials ', European Journal of Cancer, vol. 144, pp. 162-168 . https://doi.org/10.1016/j.ejca.2020.10.040
ISSN: 0959-8049
DOI: 10.1016/j.ejca.2020.10.040
Popis: BACKGROUND: Neurocognitively impaired patients with brain tumour are presumed to have reduced cognitive awareness preventing them from adequately valuing and reporting their own functioning, for instance, when providing patient-reported outcomes (PROs) such as health-related quality of life instruments. In this cross-sectional study, we aimed at assessing the concordance of neurocognitive complaints (NCCs) and objective neurocognitive functioning (NCF) as a measure of cognitive awareness.METHODS: NCF was assessed using an internationally accepted clinical trial battery. NCC was assessed using the cognitive functioning questionnaire from the Medical Outcome Study (MOS) and the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire cognitive functioning subscale. Patients were divided in cognitively impaired and unimpaired groups, based on their NCF performance. Pearson's correlation coefficients between NCF and NCCs were calculated. The same procedure was used to evaluate the correlation of NCF and QLQ-C30 CF subscale.RESULTS: Data from EORTC trials 26091 and 26101 were pooled into a data set of 546 patients. Twenty percent of patients could be characterised as unimpaired (109) and 80% as impaired (437). Impaired patients reported more cognitive complaints on the MOS scale than unimpaired patients. Correlations between NCF and NCCs were weak but significant for impaired patients and non-significant for unimpaired ones. Similar results were found for the correlation between NCF test performance and the QLQ-C30 CF subscale.CONCLUSION: Correlations between NCF test scores and complaints were weak but suggesting that neurocognitive impairment in patients with HGG does not preclude cognitive awareness. However, considering the findings of this study, we would suggest not to use PROs as a surrogate of performance-based neurocognitive evaluation.
Databáze: OpenAIRE
Externí odkaz: